Welcome to our dedicated page for IDEXX Laboratories news (Ticker: IDXX), a resource for investors and traders seeking the latest updates and insights on IDEXX Laboratories stock.
IDEXX Laboratories (IDXX) delivers essential diagnostic solutions and practice management tools for veterinary professionals worldwide. This dedicated news hub provides investors and industry stakeholders with timely updates on corporate developments shaping animal healthcare innovation.
Access official press releases and verified news covering financial results, product launches, regulatory milestones, and strategic partnerships. Our curated collection ensures transparent tracking of IDXX's advancements in in-clinic testing systems, reference laboratory services, and integrated practice software solutions.
Key updates include earnings announcements, diagnostic technology innovations, livestock health initiatives, and global expansion efforts. Bookmark this page for efficient monitoring of developments affecting veterinary diagnostics markets and IDXX's position as a leader in animal health solutions.
IDEXX Laboratories (NASDAQ: IDXX), a global leader in pet healthcare innovation, has announced it will release its 2025 first quarter financial results on Thursday, May 1, 2025, before market opening. The company will host an analyst conference call at 8:30 a.m. ET the same day.
Investors and analysts can access the live webcast, prepared remarks transcript, and Q1 2025 Earnings Snapshot through the investor relations section of IDEXX's website. An archived version of the webcast will be available after 1:00 p.m. ET and remain accessible for one year. The conference call can also be accessed via telephone using specific dial-in numbers.
IDEXX Laboratories (NASDAQ: IDXX), a leader in pet healthcare innovation, has announced its participation in two upcoming institutional investor conferences. At the BofA Securities Animal Health Summit on February 27, Mike Erickson (EVP and GM of Point of Care Diagnostics and Telemedicine) and Andrew Emerson (SVP of Corporate and CAG Finance) will engage in a fireside chat from 9:05-9:45 am EST.
Additionally, CEO Jay Mazelsky will present at the 46th Annual Raymond James Institutional Investors Conference on March 3 from 11:35 am-12:05 pm EST. Both presentations will be available via live webcasts through the company's investor relations website (www.idexx.com/investors), with archived versions accessible afterward.
IDEXX Laboratories (NASDAQ: IDXX) reported solid Q4 2024 results with revenue reaching $954 million, up 6% both reported and organic. The growth was driven by Companion Animal Group (CAG) Diagnostics recurring revenue increasing 6% reported and 7% organic.
Q4 earnings per share reached $2.62, rising 13% as reported and 10% on a comparable basis. The company's 2025 outlook projects revenue between $4,055-$4,170 million, representing 4-7% reported growth and 6-9% organic growth. EPS guidance for 2025 is set at $11.74-$12.24, indicating 10-15% reported growth.
The company plans approximately $1.5 billion in share repurchases for 2025, equivalent to ~4% of current market cap. Notable product launches include the IDEXX inVue Dx™ Cellular Analyzer and upcoming IDEXX Cancer Dx™ screening for canine lymphoma, scheduled for March 2025 release in the U.S. and Canada.
IDEXX Laboratories (NASDAQ: IDXX) has announced the launch of IDEXX Cancer Dx™, a groundbreaking diagnostic panel for early detection of lymphoma in dogs. The affordable blood test, priced as low as $15, can be integrated into annual wellness screenings and provides results within 2-3 days.
The test targets the significant market of 20 million dogs at higher risk for cancer in North America, addressing a critical need as 1 in 4 dogs in the U.S. are expected to receive a cancer diagnosis in their lifetime. Lymphoma specifically accounts for nearly 25% of new canine cancer diagnoses.
The panel features high accuracy, simple workflow integration, and includes access to IDEXX Medical Consultants. The test can detect lymphoma before clinical signs appear and will provide B-cell and T-cell phenotype classification for positive results at no additional cost. The service will be available in the U.S. and Canada in late March 2025, with plans to expand the panel over the next three years to cover the majority of canine cancer cases.
IDEXX Laboratories (NASDAQ: IDXX), a global pet healthcare innovation leader, has announced it will release its 2024 fourth quarter and full year financial results on Monday, February 3, 2025, before market opening. The company will host an analyst conference call at 8:30 a.m. ET on the same day.
Investors can access the live webcast, prepared remarks transcript, and Q4 2024 Earnings Snapshot through the company's investor relations website. The webcast recording will be available after 1:00 p.m. ET and remain accessible for one year. For telephone access, participants can dial 1-800-289-0462 or 1-323-794-2442 using passcode 803218.
IDEXX Laboratories (NASDAQ: IDXX) has announced an expansion of its share repurchase program. The company's Board of Directors has authorized the repurchase of 5 million additional shares of common stock, supplementing the existing 1.3 million shares remaining under previous authorizations as of December 3, 2024.
The repurchases can be executed through open market operations, including Rule 10b5-1 plans, or through negotiated transactions at management's discretion. The program has no specified end date and can be suspended or discontinued at any time.
IDEXX Laboratories (NASDAQ: IDXX) announced a planned CFO transition. Brian McKeon will retire effective June 1, 2025, with Andrew Emerson, current Senior VP of Corporate and CAG Finance, succeeding him as Executive VP, CFO, and Treasurer on March 1, 2025. McKeon will serve as EVP and Special Advisor until his retirement to ensure a smooth transition. Emerson brings nearly 20 years of financial experience and 9 years at IDEXX, having overseen CAG finance since 2015, which generates over 90% of IDEXX's total revenue. The company reaffirmed its 2024 full year guidance as provided on October 31, 2024.
IDEXX Laboratories reported Q3 2024 results with revenue of $976 million, showing 7% reported growth and 6% organic growth. The Companion Animal Group (CAG) segment grew 7% reported and 6% organic, while Water revenue increased 13%. Earnings per share reached $2.80, up 11% reported and 12% comparable, with operating margin expansion of 110 basis points. The company adjusted its 2024 revenue guidance to $3,865-$3,890 million, reducing previous estimates by ~1% due to macro conditions affecting U.S. veterinary clinic visits. The updated EPS outlook is narrowed to $10.37-$10.53, maintaining consistent midpoint compared to prior guidance.
IDEXX Laboratories reported strong Q3 2024 results with 7% revenue growth reaching $976 million. The company achieved 6% organic growth, driven by Companion Animal Group (CAG) performance and Water revenue growth of 13%. Earnings per share reached $2.80, up 11% as reported.
The company adjusted its 2024 revenue guidance to $3,865-$3,890 million, a reduction of $38 million, reflecting near-term impacts on growth from macro conditions affecting U.S. veterinary clinic visits. The updated EPS outlook range is $10.37-$10.53, maintaining consistent projections supported by solid operating margin performance and benefits from lower projected interest expense.
IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in pet healthcare innovation, has announced the upcoming release of its 2024 third quarter financial results. The results will be made public on Thursday, October 31, 2024, before the market opens. Following the release, the company will host an analyst conference call at 8:30 a.m. EDT on the same day.
Investors and interested parties can access a live webcast of the conference call, along with a transcript of prepared remarks and the Q3 2024 Earnings Snapshot, through the IDEXX website at www.idexx.com/investors. An archived version of the webcast will be available after 1:00 p.m. ET and remain accessible for one year. For those preferring to listen via telephone, the call can be accessed by dialing 1-800-289-0462 or 1-323-794-2442 and using the passcode 205740.